Company dossier
Gufic BioSciences
NSE:GUFICBIO · ISIN INE742B01025
- Close
- ₹382.35 29 Jul 2026
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Gufic BioSciences
Financials
Structured filings
Exchange XBRLReported financial periods
| Metric | Quarter · 31 Dec 24 | Quarter · 30 Sept 24 | Quarter · 30 Jun 24 | Quarter · 31 Mar 24 | Quarter · 31 Dec 23 | Quarter · 30 Sept 23 |
|---|---|---|---|---|---|---|
| Revenue | ₹207.8 Cr | ₹204.2 Cr | N/A | N/A | N/A | N/A |
| Profit before tax | ₹26.3 Cr | ₹29.3 Cr | N/A | N/A | N/A | N/A |
| Profit after tax | ₹19.3 Cr | ₹21.8 Cr | N/A | N/A | N/A | N/A |
| Finance cost | ₹4.9 Cr | ₹9.8 Cr | N/A | N/A | N/A | N/A |
| Impairment | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS | ₹1.93 | ₹2.17 | N/A | N/A | N/A | N/A |
Accounting lens
Research frameworkWhat deserves analyst attention
Confirm quarterly, year-to-date and annual periods before calculating growth. The table preserves the exchange period labels.
Treat scope changes as breaks in comparability and open the linked XBRL before relying on a trend.
Sector metrics and accounting choices require additional facts beyond this common cross-company layer.